Hepatitis B virus and hepatitis C virus co-infection: A therapeutic challenge

Hamzaoui, Lamine; Bouchtili, S. El; Siai, Karima; Mahmoudi, Moufida; Azzouz, Mohamed

doi:10.1016/j.clinre.2012.08.001

Cited by 13 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients should receive treatment for chronic HCV hepatitis. [34] Viral interactions will affect the therapeutic options in dually infected patients with HBV and HCV.…”

Section: Clinical Features Of Hepatitis C and Hepatitis B Co-infection:-mentioning

confidence: 99%

“…Indeed, in some patients with HBV/HCV dual infection after eradication of the dominant virus such as clearance of serum HCV RNA with peg-IFN-α and RBV the other virus then may become active (HBV reactivation). [34], [39] A recent meta-analysis showed that dually infected patients who received peg-IFN-α and ribavirin appeared with an increase in HBV replication (23%) and particularly those who achieved SVR with the anti-HCV treatment. [53] But, this phenomenon is not frequent, [23] and acute hepatitis appears to more rare.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

AlZahrani¹

2017

IJAR

View full text Add to dashboard Cite

“…These patients should receive treatment for chronic HCV hepatitis. [34] Viral interactions will affect the therapeutic options in dually infected patients with HBV and HCV.…”

Section: Clinical Features Of Hepatitis C and Hepatitis B Co-infection:-mentioning

confidence: 99%

mentioning

confidence: 99%

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

AlZahrani¹

2017

IJAR

View full text Add to dashboard Cite

“…However, other authors using the same in vitro examination techniques later reported that HBV and HCV could replicate in the same hepatocyte without any evidence of interference effects [2,20,21]. Moreover, early clinical studies suggested that in HBV/HCV coinfection, HBV proliferation was inhibited by HCV [1,[22][23][24][25], and conversely, HCV proliferation was inhibited by HBV [1,26]. However, in most coinfection cases, HCV is predominant and HBV is inactive [1,17,22,23], although there are regional differences worldwide [12].…”

Section: Gastrointestinal and Digestive Systemmentioning

confidence: 99%

“…Moreover, early clinical studies suggested that in HBV/HCV coinfection, HBV proliferation was inhibited by HCV [1,[22][23][24][25], and conversely, HCV proliferation was inhibited by HBV [1,26]. However, in most coinfection cases, HCV is predominant and HBV is inactive [1,17,22,23], although there are regional differences worldwide [12]. Furthermore, in patients with HBV/HCV coinfection, a shift in the predominant virus may occur during the infection period [27].…”

Section: Gastrointestinal and Digestive Systemmentioning

confidence: 99%

Efficacy of Treatments for Patients with Chronic Liver Disease due to Coinfection with Hepatitis B and C Viruses

Shizuma¹

2014

J Gastroint Dig Syst

View full text Add to dashboard Cite

The hepatitis B virus (HBV) and the hepatitis C virus (HCV) are the leading causes of chronic liver disease. Patients with chronic liver disease who are co infected with both HBV and HCV develop cirrhosis and hepatocellular carcinoma (HCC) more rapidly than patients with monoinfection with HBV alone or HCV alone. However, standardof-care recommendations have not been well established for patients with HBV/HCV co infection. In this study, a literature review was conducted on the efficacy of therapies for patients with HBV/HCV coinfection. Many papers reported that following combination therapy with interferon (IFN) plus ribavirin (RBV), there were no significant differences in the rate of achievement of a sustained virological response (SVR) to HCV between patients with HBV/HCV coinfection and patients with HCV monoinfection. However, the efficacy of these therapies for HBV infection in coinfected patients is complex. In patients with HBV/HCV coinfection characterized by a predominance of HCV, it is highly probable for serum hepatitis B surface antigen (HBsAg) titers to decrease or disappear during or after IFN/RBV combination therapy. On the other hand, reactivation of HBV due to the suspected inhibition of HCV replication is sometimes detected in coinfected patients during or after IFN/RBV combination therapy.

show abstract

“…However, DAAs are still challenged with unsolved issues such as elevated costs, both for development and implementation 30 , emergence of pathogen resistance 31 , poor treatment responses in selected patient groups [32][33][34][35] or drug-drug interactions leading to toxicity [36][37][38][39][40] . These problems become even more relevant in co-infections as of HIV and HCV, for which combination treatment can be a clinical challenge 38,41,42 . For example, inhibitors of viral proteases are subject to degradation by cytochrome 3A4 (CYP3A4) and co-administration of so-called booster drugs like ritonavir or cobicistat that inhibit CYP3A4 is often required.…”

Section: Many For One: Many Drugs One Targetmentioning

confidence: 99%

Antiviral drug discovery: broad-spectrum drugs from nature

et al. 2015

View full text Add to dashboard Cite

, but cannot be converted to PDF. You must view these files (e.g. movies) online.Scheme 1_(structures 1-5)_named.cdx Scheme 2_(structures 6-8)_named.cdx Scheme 3_(structure 9)_named.cdx Scheme 4_(structure 10)_named.cdx Scheme 5_ (structures 11-12) The development of drugs with broad-spectrum antiviral activities is a long pursued goal in drug discovery. It has been shown that blocking co-opted host-factors abrogates the replication of many viruses, yet the development of such host-targeting drugs has been met with skepticism mainly due to toxicity issues and poor translation to in vivo models. With the advent of new and more powerful screening assays and prediction tools, the idea of a drug that can efficiently treat a wide range of viral infections by blocking specific host functions has rebloomed. Here we critically review the state-of-the-art in broad-spectrum antiviral drug discovery. We discuss putative targets and treatment strategies, taking particular focus on natural products as promising starting points for antiviral lead development.

show abstract

Hepatitis B virus and hepatitis C virus co-infection: A therapeutic challenge

Cited by 13 publications

References 44 publications

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

Efficacy of Treatments for Patients with Chronic Liver Disease due to Coinfection with Hepatitis B and C Viruses

Antiviral drug discovery: broad-spectrum drugs from nature

Contact Info

Product

Resources

About